tiprankstipranks
Eupraxia Pharmaceuticals (EPRX)
NASDAQ:EPRX

Eupraxia Pharmaceuticals (EPRX) Cash flow

1 Followers

Eupraxia Pharmaceuticals Cash Flow

EPRX's free cash flow for Q3 2023 was C$-7.96M. For the 2023 fiscal year, EPRX's free cash flow was decreased by C$-4.44M and operating cash flow was C$-7.95M. See a summary of the company’s cash flow.
Cash Flow
TTM
Dec 22Dec 21Dec 20
Operating Cash Flow
C$ -25.09MC$ -18.78MC$ -14.64MC$ -403.78K
Investing Cash Flow
C$ 17.88MC$ 8.70MC$ -14.45MC$ 24.62K
Financing Cash Flow
C$ 28.67MC$ 13.52MC$ 49.92MC$ -626.64K
Cash Flow From Discontinued Operation
----
Other Cash Adjustment Inside Changein Cash
----
End Cash Position
C$ 95.89MC$ 24.74MC$ 20.89MC$ 150.13K
Income Tax Paid Supplemental Data
----
Interest Paid Supplemental Data
----
Issuance Of Capital Stock
C$ 21.53MC$ 13.30MC$ 37.83M-
Issuance Of Debt
C$ -193.21KC$ -185.18KC$ 12.08MC$ -390.69K
Repayment Of Debt
C$ -193.21KC$ -185.18KC$ -586.43KC$ -2.10M
Free Cash Flow
C$ -25.21MC$ -19.08MC$ -14.64MC$ -403.78K
Domestic Sales
----
Foreign Sales
----
Currency in CAD

Eupraxia Pharmaceuticals Cash Flow

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis